Hormone Intervention/ Androgen Deprivation
Posted on: 11/01/2009
Xtandi ( enzalutamide ): Moving Up Front -- A Game Changer (July-August 2013)
PCa Commentary (January-February 2013) - (1) Intermittent vs Continuous Androgen Deprivation, (2) Finasteride and Dutasteride, & (3) Intermittent Androgen Deprivation for Metastatic Prostate Cancer
Degarelix: What's Old: What's New? (November-December 2012)
MDV3100: Now FDA Approved (November-December 2012)
An Alternative to Lupron - "The Road Not Taken" (March-April 2012)
MDV3100 - Phase III "AFFIRM" Trial Demonstrates Survival Benefit (March-April 2012)
Switching Between Alpha-reductase Inhibitors (Sept-Oct 2011)
Intermittent Androgen Suppression for Prostate Cancer: Abstract 4514, Asco June 2011 (Sept-Oct 2011)
Intermittant Androgen Suppression: Findings of a Major Review (May - June 2011)
Intermittent Androgen Suppression: A Work in Progress (July-August 2010)
About Testosterone (March-April 2010)
Male Estrogen Deficiency (March- April 2010)
Intermittant Hormonal Therapy: Confirmation on Its Effectiveness (Jan-Feb 2010)
Hormone Control of Prostate Cancer in PSA Relapse Only With Combined Antiandrogen and 5 alpha-Reductace Inhibitor (Sept-Oct 2009)
Testosterone Suppression - A Word of Caution from a Large Swedish Study (Nov-Dec 2009)
Abiraterone - An Update (With contribution and review by Dr. R. Bruce Montgomery) (May-June 2009)
Antiandrogen Withdrawal; Testosterone Recovery Following Androgen Suppression (November 2008)
ABIRATERONE: A Hormone Therapy for "Hormone Refractory" Prostate Cancer - An Introduction (September 2008)
DUTASTERIDE/BICALUTAMIDE - An alternative to Lupron? Where's The Meat? (June 2008)
Testosterone-Based LHRH Dosing; Intraprostatic Androgens During Androgen Suppression; Dutasteride and Intraprostatic Androgens, and Intermittent Androgen Deprivation Combined with Finasteride (Sept 2007)
Intermittent Androgen Deprivation: Very Likely An Idea Whose Time Has Come (July 2007)
Androgen Deprivation, Diabetes, and Adverse Cardiovascular Events (July 2007)
Osteonecrosis of the Jaw, Androgen Deprivation, and Bisphosphonates (May 2007)
Androgen Deprivation Monotherapy for PCa (February 2007)
Nadir PSA after Radiation Therapy and Androgen Deprivation for Metastatic Disease (February 2007)
Primary Androgen Deprivation for Prostate Cancer (February 2007)
Intermittent Vs Continuous Androgen-Deprivation Therapy: Two Reports From ASCO 2006 (November 2006)
Adjuvant Hormone Intervention: Is The Strategy Shifting? (November 2006)
Deferred combined androgen blockage therapy using bicaultamide [80mg/d] in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy (October 2006)
Testosterone Recovery after Cessation of LH-RH Agonist Therapy (June 2006)
Androgen Deprivation and Memory Loss (April 2006)
“Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate” - Charles Ryan and Eric Small (January 2006)
Androgen Deprivation Therapy - What Method Do Men Choose? (January 2006)
PSADT And Androgen Deprivation (August 2005)
Six-Months Androgen Suppression Plus Radiotherapy - Strong Support For An Overall Survival Benefit In Men With Clinically Localized Intermediate And High Risk Prostate Cancer (October 2004)
Early Androgen Deprivation Benefits Men In High Risk disease category Who Have PSA Relapse After Radical Prostatectomy (May 2004)
Food For Thought - Keep An Open Mind (December 2003)
Hormone News - (Actually, Anti-Hormone News) (Nov 2003)
Intermittent Androgen Deprivation: Promising Theory, Results Pending. (References available) (July 2003)
KETOCONAZOLE: Further thoughts about this second-line hormone intervention (May 2003)
Prophylactic Breast Irradiation (April 2003)
CASODEX 50 mg - Where Does It Fit In? (April 2003)
Are there alternatives to Lupron or Zoladex for primary hormonal intervention? - A discussion of Proscar in combination with either Casodex or Eulexin. (February 2003)
Nomogram (on Web) predicting outcome of Zoladex [or Lupron - ed.] as treatment of rising PSA associated with and without metastatic disease. (November 2002)
Reference to DES 1 mg daily as "secondary" hormone intervention after LHRH agonist failure. (October 2002)
In This Section
